Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case–control study
European Journal of Public Health · 2025
DOI: 10.1093/eurpub/ckae219 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Public Health, 2025. Verfasst von Leonie de Munter und 19 weiteren Autor:innen. Beteiligte Einrichtung: P95 Epidemiology and Pharmacovigilance, Leuven, Belgium. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, Vaccine Efficacy, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: COVIDRIVE Consortium, AstraZeneca.
Abstract (Originalsprache)
Marketing authorization holders of vaccines typically need to report brand-specific vaccine effectiveness (VE) to the regulatory authorities as part of their regulatory obligations. COVIDRIVE (now id. DRIVE) is a European public–private partnership for respiratory pathogen surveillance and studies of brand-specific VE with long-term follow-up. We report the final VE results from a two-dose primary series AZD1222 (ChAdOx1 nCoV-19) vaccine schedule in ≥18-year-old individuals not receiving boosters. Patients (N = 1,333) hospitalized with severe acute respiratory infection at 14 hospitals in Austria, Belgium, Italy, and Spain were included in the test-negative case–control study in 2021–2023. Absolute VE was calculated using generalized additive model (GAM), generalized estimating equation (GEE), and spline-based area under the curve (AUC, measuring VE up to 6 months after the last dose of AZD1222). Overall VE (against coronavirus disease 2019 [COVID-19] hospitalization) of an AZD1222 primary series was estimated as 65% using GEE (95% confidence interval [CI]: 52.9–74.5), and 69% using GAM (95% CI: 50.1–80.9) over the 22-month study period (comparator group: unvaccinated patients). The AUC of the spline-based VE estimate was 74.1% (95% CI: 60.0–88.3). VE against hospitalization in study participants who received their second AZD1222 dose 2 months or less before hospitalization was 86% using GEE (95% CI: 77.8–91.4), 93% using GAM (95% CI: 67.2–98.6). During this study period, where mainly the severe acute respiratory syndrome coronavirus 2 Omicron variant was circulating, a two-dose primary series AZD1222 vaccination conferred protection against COVID-19 hospitalization up to at least 6 months after the last dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
- Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
- Medical and Payor Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
- Medical and Payor Statistics, BioPharmaceuticals Medical, AstraZeneca, Mölndal, Sweden.
- Preventive Medicine Department, Germans Trias i Pujol University Hospital, Badalona, Spain.
- Autonomous University of Barcelona, Bellaterra, Spain.
ORCID-Profile: Charlotte Martin
Förderung
- COVIDRIVE Consortium
- AstraZeneca
Zitieren
APA
de Munter, L., Meeraus, W., Dwivedi, A., Mitratza, M., Wyndham-Thomas, C., Carty, L., Ouwens, M., Hartig-Merkel, W., Drikite, L., Rebry, G., Casas, I., Mira-Iglesias, A., Icardi, G., Otero-Romero, S., Baumgartner, S., Martin, C., Holemans, X., Ten Kate, G. L., Bollaerts, K., & Taylor, S. (2025). Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case–control study. European Journal of Public Health. https://doi.org/10.1093/eurpub/ckae219
Vancouver
de Munter L, Meeraus W, Dwivedi A, Mitratza M, Wyndham-Thomas C, Carty L, et al. Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case–control study. European Journal of Public Health. 2025. doi:10.1093/eurpub/ckae219
BibTeX
@article{deMunter2025,
author = {de Munter, Leonie and Meeraus, Wilhelmine and Dwivedi, Akshat and Mitratza, Marianna and Wyndham-Thomas, Chloé and Carty, Lucy and Ouwens, Mario and Hartig-Merkel, Wendy and Drikite, Laura and Rebry, Griet and Casas, Irma and Mira-Iglesias, Ainara and Icardi, Giancarlo and Otero-Romero, Susana and Baumgartner, Sebastian and Martin, Charlotte and Holemans, Xavier and Ten Kate, Gerrit Luit and Bollaerts, Kaatje and Taylor, Sylvia},
title = {Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case–control study},
journal = {European Journal of Public Health},
year = {2025},
doi = {10.1093/eurpub/ckae219}
}
EUVIMED